BioNexus Gene Lab

BioNexus Gene Lab Debt

The Debt of BioNexus Gene Lab (BGLC) as of Oct 11, 2026 is 176,046.00 USD. In the previous year, Debt was 210,557.00 USD — a change of -16.39% (lower).

Debt

176,046.00USD

YoY

-16.39%

Last updated:

In 2025, BioNexus Gene Lab's total debt was 176,046.00 USD, a -16.39% change from the 210,557.00 USD total debt recorded in the previous year.

The BioNexus Gene Lab Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
82,063.00 USD
Jan 1, 2019
89,435.00 USD
Jan 1, 2020
123,419.00 USD
Jan 1, 2021
76,947.00 USD
Jan 1, 2022
56,775.00 USD
Jan 1, 2023
146,594.00 USD
Jan 1, 2024
210,557.00 USD
Jan 1, 2025
176,046.00 USD
The BioNexus Gene Lab Debt history
YEARDebtYoY
176,046.00USD-16.39%
210,557.00USD+43.63%
146,594.00USD+158.20%
56,775.00USD-26.22%
76,947.00USD-37.65%
123,419.00USD+38.00%
89,435.00USD+8.98%
82,063.00USD—
Access this data via the Eulerpool API
Get Free API Key

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Debt Details

Understanding BioNexus Gene Lab's Debt Structure

BioNexus Gene Lab's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing BioNexus Gene Lab's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to BioNexus Gene Lab’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in BioNexus Gene Lab’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about BioNexus Gene Lab stock

Debt of BioNexus Gene Lab is 176,046.00 USD in 2025.

Debt of BioNexus Gene Lab changed from 210,557.00 USD to 176,046.00 USD, representing a -16.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's BioNexus Gene Lab historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — BioNexus Gene Lab

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioNexus Gene Lab